Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFOX + tegafur-uracil
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
FOLFOX + tegafur-uracil is a combination chemotherapy regimen used primarily in the treatment of colorectal cancer. FOLFOX consists of folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. Tegafur-uracil (UFT) is an oral combination of the prodrug tegafur and uracil; it acts as an alternative oral source of 5-FU with uracil inhibiting dihydropyrimidine dehydrogenase to increase 5-FU bioavailability. The combined regimen targets rapidly dividing tumor cells through multiple mechanisms: - Oxaliplatin forms DNA crosslinks, inhibiting DNA replication and transcription. - Fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis. - Tegafur is converted to 5-FU in the liver, providing sustained cytotoxic activity. This multi-agent approach increases antitumor efficacy by attacking cancer cells at different points in their cell cycle and metabolic pathways[1][2][6][10].
- Brand names
- Uftoral
- Other names
- folinic acid + fluorouracil + oxaliplatin + tegafur/uracilleucovorin calcium + 5-fluorouracil + oxaliplatin + tegafur/uracil
02
Targets
DNADPYD (Dihydropyrimidine dehydrogenase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on FOLFOX + tegafur-uracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFOX + tegafur-uracil.